主页
市场
图表与思路
Algo
新闻
Store
经纪商
下载
经济日历
交易信号
网页端
键入
/
进行搜索:@user,$symbol
查找
登录
创建账户
中文
English
Русский
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
TSHA
#1816
Taysha Gene Therapies, Inc. Common Stock
4.5
3
+0.44%
版块:
基础:
利润货币:
日范围
年范围
日变化
+0.44%
每月变动
-4.43%
6个月变化
+51.51%
年变化
+177.91%
前一天收盘价
4.5
1
Open
4.5
3
Bid
Ask
Low
4.5
3
High
4.5
3
交易量
115
市场
股票
医疗保健
TSHA
Open full chart
Financials
Overview
声明
Statistics
Dividends
Quarterly
Annual
Value
2020
2021
2022
2023
2024
TTM
Key stats
Total common shares outstanding
37.76 M
38.47 M
63.47 M
187.02 M
205 M
—
Valuation ratios
Enterprise value
750.94 M
299.12 M
51.76 M
175.86 M
215.62 M
1.31 B
Price to earnings ratio
—
—
-0.58
-1.78
-4.81
-25.6
Price to sales ratio
—
—
38.68
12.85
51.93
318.86
Price to cash flow ratio
—
—
1.09
2.72
5.33
28.41
Price to book ratio
—
—
101.89
2.65
6.05
10.2
Enterprise value to EBITDA ratio
—
—
—
—
—
—
Profitability ratios
Return on assets %
0.23
0.82
1.31
0.65
0.56
0.46
Return on equity %
0.24
1.83
174.94
1.49
1.25
0.91
Return on invested capital %
5 101.07
2 243.62
845.6
456.59
882.31
1 286.18
Gross margin %
—
100
100
100
100
—
Operating margin %
—
-15.75 K
6 497.88
468.83
1 097.55
—
EBITDA margin %
—
—
—
—
—
—
Net margin %
—
-15.87 K
6 640.56
722.06
1 071.62
—
Liquidity ratios
Quick ratio
—
—
—
—
—
—
Current ratio
36.17
3.08
1.54
4.08
5.42
33.72
Inventory turnover
—
—
—
—
—
—
Asset turnover
—
-0
0.01
0.1
0.05
0.04
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
—
0.17
0.3
0.23
0.27
0.86
Long term debt to total equity ratio
—
0.39
40.01
0.54
0.61
1.78
Per share metrics
Operating cash flow per share
—
—
2.01
0.63
0.32
0.29
EBIT per share
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
Cash per share
—
—
2
1.24
0.56
2.88
Net current asset value per share
—
—
2.19
1.29
0.57
2.93
Tangible book value per share
—
—
0.02
0.65
0.29
1.94
Working capital per share
—
—
0.77
0.97
0.46
2.57
Book value per share
—
—
0.02
0.65
0.29
1.94
新闻
从实验室到股市飙升:富国银行选出2026年SMID-Cap生物科技领军股
Stifel 重申 Neurogene 股票买入评级,认为其具有可行安全边际
Stifel reiterates Buy rating on Neurogene stock, cites viable safety margin
Taysha为Rett综合征基因疗法关键试验给首位患者用药
Taysha doses first patient in pivotal Rett syndrome gene therapy trial
泰莎基因治疗股价创52周新高至5.98美元
Taysha Gene Therapies stock hits 52-week high at $5.98
2026美股生物科技板块怎么投资?杰富瑞:关注这6大首选股、7大潜力标的和5大并购目标
生物科技股:杰富瑞列出2026年六大首选股票
Biotech Stocks: Jefferies Names its 6 Top Picks for 2026
Citizens维持Taysha Gene Therapies股票的市场跑赢评级
Citizens reiterates Market Outperform rating on Taysha Gene Therapies stock